再発または転移性外陰がんに対するAK104の第II相試験
再発または転移性外陰がんの治療におけるAK104の多施設共同非盲検第II相研究
This is a multicenter, open-label, phase II clinical study, aiming to the evaluate the efficacy and safety of AK104 (an anti- PD-1 and CTLA-4 bispecific antibody), alone or combined with chemotherapy, in subjects with recurrent or metastatic vulvar cancer not amenable to curative surgery or radiotherapy.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Fujian
-
Fuzhou、Fujian、中国、350000
- Clinical oncology school of Fujian Medical University, Fujian Cancer Hospital
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510000
- Sun Yant-Sen Memorial Hospital
-
-
Hebei
-
Shijiangzhuang、Hebei、中国、050000
- The Fourth Hospital of Hebei Medical University
-
-
Liaoning
-
Shenyang、Liaoning、中国、110042
- Liaoning Cancer Hospital & Insitut
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、300000
- Tianjin medical university Cancer Institut & Hospital
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310022
- Zhejiang Cancer Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Age >=18 and <=80. ECOG of 0 or 2. Life expectancy ≥ 3 months. Histologically confirmed vulvar cancer (squamous cell carcinoma or adenosquamous carcinoma), not amenable to curative surgery or radical radiotherapy.
For Cohort A, subjects should have experienced failure on at least one previous systemic therapy, or intolerance to standard therapy.
At least one measurable tumor lesion per RECIST v1.1. Adequate organ function as assessed in the laboratory tests. Female subjects of childbearing potential must have a negative serum pregnancy test prior to the the first administration and agree to use effective methods of contraception
Exclusion Criteria:
Subjects with other histopathological types of vulvar cancer, such as melanoma, sarcoma, etc.
Systemic or curative (surgery or radiotherapy) anti-tumor therapy within 4 weeks prior to the first administration.
Previous treatment with immune checkpoint inhibitors (e.g., anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, etc.).
Active or potentially recurrent autoimmune disease.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Cohort A: AK104
AK104 monotherapy |
AK104 15mg/kg intravenously(IV) every 3 weeks (Q3W), until progressive disease, unacceptable toxicity, completion of 2 years treatment or withdrawal of consent.
他の名前:
|
|
実験的:Cohort B: AK104+chemotherapy
AK104 combined with platinum-based chemotherapy (paclitaxel+ cisplatin or carboplatin) |
AK104 (10 mg/kg) + paclitaxel (175 mg/m2)+ cisplatin (50 mg/m2) or carboplatin (AUC 4-5) , IV, Q3W, for up to 6 cycles, followed by maintenance therapy of AK104 10 mg/kg Q3W until disease progression, intolerable toxicity, withdrawal of consent, or completion of 2 years treatment. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective response rate (ORR) assessed by investigator.
時間枠:Up to approximately 1 years
|
The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR per RECIST v1.1 |
Up to approximately 1 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free survival (PFS) Assessed by investigator
時間枠:Up to approximately 2 years
|
The time from the first administration to the first documented progressive disease (PD) or death due to any cause, whichever occurs first |
Up to approximately 2 years
|
|
Duration of Response (DOR) Assessed by investigator
時間枠:Up to approximately 2 years
|
Measured from the date of partial or complete response to therapy until the disease progression per RECIST v1.1 criteria |
Up to approximately 2 years
|
|
Disease control rate (DCR) Assessed by investigator
時間枠:Up to approximately 1 years
|
The proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥6 weeks) based on RECIST |
Up to approximately 1 years
|
|
Time to Response (TTR) Assessed by investigator
時間枠:Up to approximately 1 years
|
The time from the first administration to the date of documented CR or PR |
Up to approximately 1 years
|
|
Overall survival (OS)
時間枠:Up to approximately 2 years
|
The time from the first administration to death due to any cause |
Up to approximately 2 years
|
|
Adverse Events (AEs)
時間枠:Up to approximately 2 years
|
Characterization of incidence, severity and abnormal clinically significant manifestation or laboratory findings. |
Up to approximately 2 years
|
|
serum concentrations of AK104
時間枠:Up to approximately 2 years
|
assessment of PK include serum concentrations of AK104 at different timepoints after study drug administration |
Up to approximately 2 years
|
|
Antidrug antibodies (ADA) of AK104
時間枠:Up to approximately 2 years
|
Proportion of subjects who develop detectable anti-drug antibodies (ADAs) |
Up to approximately 2 years
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。